Carvedilol: Therapeutic Application and Practice Guidelines

Current knowledge of the mechanisms contributing to progression of heart failure suggests that therapies that limit or interfere with the consequences of neurohormonal activation and improve myocardial energetics appear to be most beneficial. Carvedilol, a nonselective β‐adrenergic blocker with peri...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 1998-07, Vol.18 (4), p.729-737
Main Authors: Bleske, Barry E., Gilbert, Edward M., Munger, Mark A.
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Biological and medical sciences
Carbazoles - therapeutic use
Cardiovascular system
Heart Diseases - drug therapy
Humans
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Practice Guidelines as Topic
Propanolamines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current knowledge of the mechanisms contributing to progression of heart failure suggests that therapies that limit or interfere with the consequences of neurohormonal activation and improve myocardial energetics appear to be most beneficial. Carvedilol, a nonselective β‐adrenergic blocker with peripheral vasodilating properties, reduces mortality, slows progression of disease, and improves quality of life in patients with heart failure when added to standard therapy. When administered according to recommended guidelines, carvedilol is well tolerated. Clinical guidelines on the use of carvedilol in heart failure are provided.
ISSN:0277-0008
1875-9114
DOI:10.1002/j.1875-9114.1998.tb03895.x